Hematological Malignancy Clinical Trial
Official title:
An Exploratory, Open-Label, Single Center Study of CXCR4-targeted PET/CT Imaging for Evaluation of Hematological Malignancies
The incidence and mortality of hematological malignancies remain high. Although 18F-FDG PET/CT imaging is the most common molecular imaging technique used in clinic, the non-specific uptake of 18F-FDG leads to the problems of false negative or positive in hematological malignancies, which makes it difficult to diagnose and evaluate the efficacy. CXCR4 (C-X-C Chemokine Receptor Type 4) is overexpressed in various hematological malignancies, and is associated with poor prognosis. CXCR4-targeted molecular imaging, such as 68Ga-pentixafor PET/CT imaging, has an important potential in hematological malignancies. Therefore, this study will evaluate the efficacy of CXCR4-targeted PET/CT imaging for diagnosis and staging of hematological malignancies, compared with 18F-FDG PET/CT imaging.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04932967 -
Use of nMoABs for the Treatment of COVID-19 in Patients With HM.
|
||
| Not yet recruiting |
NCT02900768 -
Effects of Exercise on Allogeneic Stem Cell Transplant
|
N/A | |
| Recruiting |
NCT04082910 -
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05510089 -
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
|
N/A | |
| Terminated |
NCT04093622 -
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
|
||
| Recruiting |
NCT06106360 -
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
|
||
| Recruiting |
NCT06225856 -
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
|
Phase 1 | |
| Recruiting |
NCT02828462 -
Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics
|
||
| Completed |
NCT01714180 -
Effect of Body Mass on Acyclovir Pharmacokinetics
|
N/A | |
| Completed |
NCT03241550 -
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
|
Phase 1 | |
| Active, not recruiting |
NCT04684108 -
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
|
Phase 1 | |
| Completed |
NCT02598752 -
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
|
||
| Completed |
NCT02880709 -
The Effect of Special Diets in Hematological Cancer Patients
|
Phase 4 | |
| Completed |
NCT00894049 -
A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation
|
Phase 2 | |
| Completed |
NCT04687982 -
Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).
|
N/A | |
| Completed |
NCT00897260 -
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders
|
N/A | |
| Recruiting |
NCT03850366 -
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
|
Phase 2 | |
| Not yet recruiting |
NCT06066255 -
PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
|
Phase 2 | |
| Enrolling by invitation |
NCT05364359 -
Individual Dietary Counseling Based on Taste-tests in Patients With Hematological Cancer in Cytostatic Therapy
|
N/A | |
| Recruiting |
NCT04841447 -
Membrane Target Detection for Leukemia Treatment
|